The 5‐HT_1A receptor agonist, 8‐OH‐DPAT, attenuates long‐lasting pain in imiquimod‐induced psoriasis in mice

Abstract

Psoriasis is perhaps the most prevalent immune-related skin disease in adults. Itch and pain are common symptoms among psoriasis patients, which are not yet fully understood. 1 Up to 42% of the psoriasis patients have pain 2 harming their quality of life. 3 Psoriasis physiopathology involves activated lymphocytes, antigen-presenting cells, neutrophils, keratinocytes and a large number of mast cells 4 which can synthesize and store serotonin or 5-hydroxytryptamine (5-HT) as well as cytokines related to the development and maintenance of chronic pain. 5,6 Pain is considered an unpleasant sensory and emotional experience, associated with actual or potential tissue injury, which can be described in terms of such injury. 7 In terms of pain processing, a noxious stimulus can provoke: (a) a reduction in the pain threshold (allodynia, ALD), characterized by a painful sensation caused by a non-painful stimulus, and

Oral small molecules: new therapeutic targets in psoriasis

“…La catepsina S tiene un papel importante en la presentación de antígenos por el complejo mayor de histocompatibilidad (MHC) de clase II y en la degradación de la matriz extracelular. Además, es responsable de la activación de la IL-36γ (46). Ausente en la piel humana normal, se ha encontrado expresión de catepsina S en los queratinocitos psoriásicos.…”